Chemo gel delivered directly to kidney tumors: can it help when other options run out?
NCT ID NCT05494411
First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time
Summary
This named patient program gives doctors controlled, pre-approval access to a mitomycin gel called JELMYTO for specific patients with cancer of the renal pelvis or ureter. It is for people in select countries where the treatment is not yet approved and who have exhausted other options. A prescribing physician requests the drug on behalf of a named patient and judges whether the patient is suitable and likely to benefit.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- mitomycin, a chemotherapy drug delivered as a gel into the kidney's urine-collecting system
- What this could lead to
- If the program shows the gel helps these patients, it could support wider approval and routine access in countries where it is not yet authorized.
- What could go wrong
- This is not a controlled trial, so it cannot prove the treatment works. Mitomycin can irritate the urinary tract and cause pain or bleeding, and access depends on a doctor's request and local rules.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients who are suitable to receive JELMYTO and for whom there is reasonable expectation that JELMYTO may provide clinical benefit based on the medical judgment of their prescribing physician.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Urothelial cancer of renal pelvis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can intensified chemotherapy before surgery clear bladder tumors?
- Chemo combo tested as backup for bladder cancer that outsmarts First-Line therapy
- Can tumor genes decide who keeps their bladder?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Can a new drug shrink advanced solid tumors?
- Can a radioactive antibody light up hidden tumors on PET scans?